About VCRO
Services
News
Contact us
- Contact formLet’s get in touch
- Location
English/繁中版/简中版

/

In

Risks and Considerations

Industry news

U.S. FDA Releases Draft Guidance on Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics (Part 1.)

•

Mar 24

Can’t find something?

Search

Fresh Articles

U.S. FDA Releases Draft Guidance on Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics (Part 3.)

2025-04-10
U.S. FDA Releases Draft Guidance on Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics (Part 2.)

2025-04-01
U.S. FDA Releases Draft Guidance on Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics (Part 1.)

2025-03-24

Keep it social

Categories

Industry news (6)
VCRO express (56)

Tags

Accelerated Approval AI and Xun Exosome Single Thermotherapy Benefiting Regeneration Double Method CDMO Cell therapy clinical evidence Confirmatory Trials epidemiological Evidentiary Criteria Exosome FDA Information Transparency Intermediate Clinical Endpoints Marketing and Advertising NASH pathophysiological Progress Updates pulmonary tuberculosis Regeneration Dual Method Risks and Considerations thalassemia VCRO Withdrawal 維州維州生技維州生物維州生物科技維州生物科技股份有限公司

Uphold the belief of “Professionalism, Experience and Trustworthiness”.

Virginia Contract Research Organization Co., Ltd.

3F, No. 2, Ln. 258, Ruiguang Rd., Neihu District, Taipei 114, Taiwan (Times Plaza)

Tel：+886-2-2657-5399

Fax：+886-2-2657-9678

Virginia Contract Research Organization (Shanghai) Co., Ltd.

7th Floor, Building C, Nanfeng City, 100 Zunyi Road, Changning District, Shanghai

Tel：+86-13795244528

Links

Professional Services

Socials

Contact us

customer@vcro.com.tw

© 2025 Virginia Contract Research Organization Co., Ltd. All rights Reserved.

Scroll Up